OMER (Omeros) Margin of Safety % (DCF Dividends Based) : N/A (As of Dec. 15, 2024)

View and export this data going back to 2009. Start your Free Trial

What is Omeros Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Omeros's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

Competitive Comparison of Omeros's Margin of Safety % (DCF Dividends Based)

For the Biotechnology subindustry, Omeros's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Omeros's Margin of Safety % (DCF Dividends Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Omeros's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Omeros's Margin of Safety % (DCF Dividends Based) falls into.

Omeros Margin of Safety % (DCF Dividends Based) Related Terms

Thank you for viewing the detailed overview of Omeros's Margin of Safety % (DCF Dividends Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Omeros Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omeros Corp (NAS:OMER) » Definitions » Margin of Safety % (DCF Dividends Based)

Comparable Companies

Traded in Other Exchanges

0KBU:UK 3O8:Germany 3O8:Germany

Address

201 Elliott Avenue West, Seattle, WA, USA, 98119

Website

https://www.omeros.com

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Executives

Demopulos Gregory A Md	director, 10 percent owner, officer: Chairman, CEO & President	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Demopulos Peter A Md	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Arnold C Hanish	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Thomas J. Cable	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Diana T. Perkinson	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Michael A Jacobsen	officer: VP Finance and CAO	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Kurt Zumwalt	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Peter B Cancelmo	officer: See Remarks	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Thomas F. Bumol	director	201 ELLIOT AVENUE WEST, SEATTLE WA 98119
Marcia S. Kelbon	officer: VP Patent and General Counsel	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Ray Aspiri	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Hood Leroy E. Md Phd	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Rajiv Shah	director	C/O ARCADIA BIOSCIENCES, INC., 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Daniel K Spiegelman	director	MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Jean-philippe Tripet	director	1420 FIFTH AVENUE, SUITE 2600, SEATTLE WA 98101-2347